Episurf Medical’s first US VAC approval
Today, Episurf Medical (Nasdaq: EPIS B) announces the first approval for its Episealer® Patellofemoral System from a hospital Value Analysis Committee (VAC). Value analysis committees allow hospitals to make informed decisions regarding the selection of medical devices, technologies, and services within their facility. They review factors such as clinical efficacy, patient outcomes, safety, cost-effectiveness, and overall value proposition of the products and services under consideration. Approval from a hospital’s VAC is a near-mandatory step required by every hospital or hospital system prior to having the ability to conduct business, and frequently represents the final step before the purchasing of products can commence. Surgeon support for the product or service is critical throughout the process.
“We have VAC processes ongoing at several hospital and surgical centers, and about 20 distributors are already contracted throughout the US. Surgeons appreciate our technology, and we look forward to continuing this exciting strategic initiative, the launch of the Episealer® Patellofemoral System”, says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 7 July 2023.
Tags: